Mihail Obrocea, M.D.
About Mihail Obrocea, M.D.
Mihail Obrocea, M.D. serves as the Chief Medical Officer and Head of Clinical Development at MAIA Biotechnology, Inc., bringing over 25 years of experience in the pharmaceutical and biotechnology sectors, particularly in drug development for cancer therapies. He has held various leadership roles in notable companies and has a strong academic background in medicine and oncology.
Current Role at MAIA Biotechnology
Mihail Obrocea, M.D. serves as the Chief Medical Officer (CMO) and Head of Clinical Development at MAIA Biotechnology, Inc. since 2021. He operates remotely from South San Francisco, California, while overseeing clinical strategies and development initiatives for the company. His role involves leading efforts in drug development, particularly in the field of immuno-oncology and cell therapy.
Professional Experience in Pharmaceutical Industry
Mihail Obrocea has over 25 years of experience in the pharmaceutical and biotechnology sectors. His career includes significant roles at various organizations, such as serving as the Clinical Lead for the Allogeneic CAR T Franchise at Atara Biotherapeutics from 2019 to 2021, and as Head of US Clinical Development at Nanobiotix from 2016 to 2017. He has also held leadership positions at SFJ Pharmaceuticals Group, Juno Therapeutics, MedImmune, and Pharmacyclics, focusing on clinical development and medical affairs in oncology.
Educational Background and Medical Training
Mihail Obrocea completed his Doctor of Medicine (MD) at Carol Davila University of Medicine and Pharmacy in Bucharest, Romania, from 1979 to 1985. He furthered his education by studying Internal Medicine at Yale University School of Medicine, where he completed his internship and residency from 1993 to 1996. He also holds a Master of Science in Molecular Biology from the University of Ottawa, achieved from 1990 to 1992, and completed a Hematology/Oncology Fellowship at Geisel School of Medicine at Dartmouth from 1996 to 1999.
Contributions to Cancer Research Publications
Mihail Obrocea has co-edited two significant books focused on cancer vaccines: 'Cancer Vaccines-From Research to Clinical Practice' and 'Cancer Vaccines-Challenges and Opportunities in Translation'. These publications contribute to the understanding and advancement of cancer vaccine research and its application in clinical settings.
Expertise in Hematology and Oncology
Mihail Obrocea possesses extensive expertise in hematology and oncology, particularly in clinical research and development. His focus areas include immuno-oncology and cell therapy, with a strong background in drug development processes involving various therapeutic modalities such as cancer vaccines, antibodies, and cytotoxic agents.